Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on May 2, 2024. The filing reports on a corporate action regarding a previously announced rights offering intended to raise capital for the Company.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric disclosed relates to the potential capital raise:
- Target Gross Proceeds: Up to $60,000,000 (assuming full subscription).
- Units to be Offered: Up to 6,000,000 Units.
- Subscription Price: The lesser of $10.00 (Initial Price) or the volume-weighted average price of the common stock over the ten trading days preceding the expiration date (Alternate Price).
Material Changes and Offering Structure
The Board of Directors has set the record date for the Rights Offering as May 16, 2024. Key structural details include:
- Composition of Units: Each Unit consists of one share of common stock and two warrants.
- Warrant Terms: Each warrant allows the purchase of one-half of one share. The exercise price is 110% of the per-Unit subscription price. Warrants are exercisable immediately upon completion and expire on the fifth anniversary.
- Redemption Rights: The Company may redeem warrants for $0.01 per underlying share if the stock price exceeds 150% (for one warrant) or 200% (for the other) of the exercise price for 20 consecutive trading days, subject to a three-month lockout period post-issuance.
- Expiration: The offering is currently contemplated to expire on June 13, 2024.
Guidance, Outlook, and Risks
The Company expects to receive gross proceeds of up to $60 million, less offering expenses, if fully subscribed. The offering is contingent upon the effectiveness of a registration statement on Form S-3, which was filed on April 3, 2024, and amended multiple times through April 30, 2024, but has not yet become effective. No sales or offers to buy may occur until the registration statement is effective. Investors are advised to review the final prospectus and related SEC filings for complete risk information.
Investor Verification Checklist
- Verify the effectiveness status of the Form S-3 registration statement on the SEC EDGAR database.
- Confirm the final subscription price once the volume-weighted average price is calculated near the expiration date.
- Review the final prospectus for specific underwriting agreements, dilution effects, and use of proceeds.
- Monitor the stock price relative to the 150% and 200% redemption thresholds for the warrants.